Avedro, Inc. Email Format

PharmaceuticalsMassachusetts, United States51-200 Employees

Avedro, Inc. is a commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependence on eyeglasses or contact lenses. It is headquartered at 230 Third Avenue in Waltham, Massachusetts, United States, and employs 51 to 200 people. Avedro's Corneal Remodeling Platform comprises the KXL and Mosaic systems, which deliver ultraviolet A light, together with proprietary single-use riboflavin formulations that enable corneal collagen cross-linking in minimally invasive outpatient procedures. The platform is intended to strengthen, stabilize, and reshape the cornea to treat corneal ectatic disorders and refractive conditions. In 2019, Avedro completed an initial public offering and was acquired by Glaukos later that year.

Get verified Avedro, Inc. emails free

Company overview Employee directory